You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.

    SBC: Antiger Therapeutics Inc.            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT The mission of Antiger Therapeutics Inc. is to develop novel immunotherapies for transplant recipients to improve long-term graft outcomes and minimize adverse effects. Antibody-mediated rejection (AMR) is a leading cause of graft loss, with over 3000 new cases per year in the United States and estimated market size of $90 million. However, this estimate is likely to under ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections

    SBC: FIMBRION THERAPEUTICS INC            Topic: NIAID

    1 ABSTRACT. Urinary tract infections (UTI) are extremely common world-wide, and can lead to serious2 complications, including renal scarring and urosepsis. Standard-of-care treatments rely on antibiotics: empiric3 treatment for uncomplicated UTI (uUTI), broad-spectrum for complicated UTI (cUTI), and long-term prophylaxis4 for recurrent UTI (rUTI). This constant antibiotic exposure not only disrupt ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia

    SBC: Iveena Delivery Systems, Inc.            Topic: NEI

    Project Summary Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product. The prevalence of myopia and high myopia are increa ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy

    SBC: ABBRATECH INC.            Topic: 300

    ABSTRACT Current therapeutic antibodies target the cell surface and within the external cellular environment. Yet intracellular proteins make up half of the proteome. Having a facile means of targeting those intracellular proteins for the generation of therapeutic antibodies would be highly desirable. Targeting MHC complexed with neoantigens from intracellular proteins would greatly allow the gene ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of an empathetic chatbot to monitor perinatal mental health longitudinally

    SBC: Poisera, Inc.            Topic: 104

    1 ABSTRACT2 One in five pre- or postnatal women will develop a perinatal mood disorder (PMD). While temporary and3 treatable, 50-65% of mothers with PMD symptoms never receive a diagnosis or treatment due to inadequate4 screening practices. PMDs remain undetected because mothers do not trust clinicians due to fear of judgment,5 stigma, or even loss of parental rights. Untreated PMDs increase risk ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Augmented Reality Personalized Motion Tracking Assessment and Improvement Technology for Fall Prevention for the Spanish Speaking Hispanic/Latino Population in a Community Setting Using Mobile Phone

    SBC: KINIMA, INC.            Topic: NIA

    More than 1 in 4 people 65 and older fall each year, leading to more than $50 billion in annual spending for treatment. This cost is on an upward trajectory. We have less understanding of the impact of falls and risk in the Spanish-speaking Hispanic/Latino population. Although a variety of community-based public health programs are addressing fall prevention, these programs are in English and are ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Compact Liquid Chromatography for Routine Screening in Drug Treatment Centers

    SBC: AXCEND LLC            Topic: NIDA

    Project Summary The Substance Abuse and Mental Health Services Administration (SAMHSA) has set guidelines for illicit drug monitoring for both screening and confirmatory tests. Point-of-care (POC) screening assays usually rely upon immunoassays that lack specificity among compounds in a given drug class. Confirmation testing usually employs chromatography coupled to mass spectrometry (MS), which i ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Feasibility of a dual English/Spanish mobile augmented reality pain assessment app to reduce postoperative prescription opioid use in Hispanic/Latino pediatric and adolescent cancer patients

    SBC: ALTALITY, INC.            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT OF PARENT GRANT Hispanic/Latino youth are at the highest risk for prescription opioid misuse for pain indications amongst all minority populations in the United States. There are few legitimate clinical indications for prescribing opioids to children and adolescents, as early opioid use is a known “gateway” to adulthood dependence and substance abuse disorders. Cancer ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.

    SBC: Shift Pharmaceuticals Holdings, Inc.            Topic: 106

    Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Microneedle Delivery of Trospium Chloride Optimized for Improved Tolerance and Patient Outcomes in Overactive Bladder Disease

    SBC: TSRL, INC.            Topic: NICHD

    Abstract Overactive bladder (OB) is a disease that afflicts both men and women and is driven by the aging population with a prevalence estimated as high as 39% in the US and 45% for all women over 65. OB is accompanied with a significant loss of quality of life with documented increases in falls, anxiety, and depression. The muscarinic antagonists (anticholinergics) are the primary drugs for treat ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government